Regeneron: Here‘s Your Next $12,000 Wonder Drug
July 24, 2015 at 15:19 PM EDT
Insurers watch out. Here comes another expensive prescription drug. Regeneron (REGN) and its partner Sanofi (SNY) beat rival Amgen (AMGN) to win U.S. approval for a new class of cholesterol-lowering drugs, called PCSK-9 inhibitors. The FDA today approved Praluent, which provides an alternative to high-risk patients unable to get their cholesterol levels to desirable levels [...]